MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
Abstract Treatment of non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) activating mutation with EGFR-TKIs has achieved great success, yet faces the development of acquired resistance as the major obstacle to long-term disease remission in the clinic. MET (or c-MET...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-06-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | http://link.springer.com/article/10.1186/s13045-019-0759-9 |